NCCN Guidelines® Insights - Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).

NCCN Guidelines® Insights - Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate are intended to serve as a resource for health care providers to identify individuals who may benefit from cancer risk assessment and genetic co

Behind the Guidelines: Insights into the Standard of Care in Oncology 2026 (NCCN Guidelines® Insights 2026)

In each issue of JNCCN, NCCN panel members shed light on the deliberation process behind the creation of the NCCN Guidelines, clarifying why and how these important decisions are made.

NCCN Guidelines® Insights - Small Cell Lung Cancer, Version 2.2026

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer provide recommendations for diagnostic workup, staging, and treatment.

NCCN Guidelines® Insights - Soft Tissue Sarcoma, Version 1.2025
The treatment landscape for soft tissue sarcomas (STS) is evolving constantly. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for STS specific to surgical management and systemic therapy recommendations for various subtypes.
NCCN Guidelines® Insights - Breast Cancer, Version 5.2025
The treatment landscape of invasive early-stage and metastatic breast cancer is evolving constantly. These NCCN Guidelines Insights focus on recent updates included in the most recent version (version 5.2025) of the NCCN Guidelines for Breast Cancer specific to workup, locoregional therapy, surveillance, and systemic neoadjuvant/adjuvant therapy recommendations for invasive, nonmetastatic breast cancer.
NCCN Guidelines® Insights - B-Cell Lymphomas, Version 3.2025
These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, MCL, and DLBCL.
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 7.2025
These NCCN Guidelines Insights discuss recent updates to the NCCN Guidelines, with a focus on systemic therapy options for the treatment of patients with nonmetastatic NSCLC and the corresponding molecular testing considerations.
NCCN Guidelines® Insights - Uterine Neoplasms, Version 3.2025
These NCCN Guidelines Insights summarize the panel’s deliberations on the new FIGO 2023 staging system and updates on the new systemic therapy recommendations for the management of endometrial cancer.
NCCN Guidelines® Insights - Thyroid Carcinoma, Version 1.2025
These NCCN Guidelines Insights focus on the panel’s most recent recommendations regarding systemic therapies for thyroid carcinoma as well as the supporting clinical data.

Pages

Subscribe to RSS - Monograph/Journal Supplement